drugset
drugset / Trial / NCT04201145

Pembrolizumab + Defactinib In Pleural Mesothelioma

NCT04201145 ↗

Phase 1 Withdrawn Raphael Bueno, MD Merck Sharp & Dohme LLC · collab
Non-randomizedSequentialOpen-labelTreatment

Summary

This research study is studying a new drug combination of Pembrolizumab and Defactinib followed by surgical resection possible treatment for resectable Malignant Pleural Mesothelioma (MPM). The names of the study drugs involved in this study are: * Pembrolizumab * Defactinib

Timeline

Start
2020-09
Primary completion
2021-12-31
Completion
2022-12-31

Outcome

Outcome not reported

Stopped (Business): “Funding complications coupled with competing scientific objectives”

Drugs

EvaluationDrugModalityDoseRoute
Subject Defactinib Small molecule — Oral
Subject Pembrolizumab Monoclonal antibody — Intravenous

Indications

malignant pleural mesothelioma